Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia
MT with either decitabine or chemotherapy can improve outcomes of AML patients in this real-world cohort. Decitabine maintenance exhibits better tolerability compared with chemotherapy and enhances survival in specific patient subgroups.
Authors
- Sujun Gao
- Long Su (ORCID: https://orcid.org/0000-0002-5360-468X)
- Qiu-Ju Liu
- Zhifeng Wei
- Xiao-Liang Liu
- Jia-Qi Yan
- Ye-Hui Tan
- Hai Lin
Institutions
- Jilin University (CN)
- First Hospital of Jilin University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.3389/fphar.2026.1753030
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Jilin University
- First Hospital of Jilin University